In recent weeks, there has been some controversy spread on various forums about Benitec's (OTCPK:BNIKF) management deliberately rejecting patients for enrollment in their HCV TT-034 clinical trial. This false information has grown out of frustration with the four month delay in dosing. Some of the supporters of this view have continued to push this line despite management's statements to the contrary.
This argument can now be put to bed because today the company has announced that the first patient in the TT-034 trial has now been dosed. This is a groundbreaking moment for the company as this is the first systemically administered, in-person, ddRNAi drug to trialed in the world. The management team at Benitec and a the medical team at Duke Medical deserve some credit for this achievement.
The progress of the patients will be monitored and reported on by an independent team.
The next milestone will be reached when the first safety results are known. It is anticipated that the first two cohorts will only produce safety data, efficacy results will only be known when the results from the later cohorts are available.
For Benitec longs, the light at the end of the tunnel has just gotten a lot brighter.